We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

53 hedge funds and large institutions have $339M invested in Stoke Therapeutics in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

32% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 19

13% more funds holding

Funds holding: 47 → 53 (+6)

3.46% more ownership

Funds ownership: 45.24% → 48.7% (+3.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

17% less capital invested

Capital invested by funds: $409M → $339M (-$70.4M)

Holders
53
Holders Change
+6
Holders Change %
+12.77%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
25
Increased
13
Reduced
9
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$20.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$16M
3
BlackRock
BlackRock
New York
+$16M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$12.9M
5
Millennium Management
Millennium Management
New York
+$4.05M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$7.29M
2
AI
Atom Investors
Texas
-$5.82M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.77M
4
O
OrbiMed
New York
-$3.79M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$9K +$11.3K +407 New
VFA
52
Valeo Financial Advisors
Indiana
$3K +$3.74K +134 New
AI
53
Atom Investors
Texas
– -$5.82M -199,513 Closed
O
54
OrbiMed
New York
– -$3.79M -130,000 Closed
Citadel Advisors
55
Citadel Advisors
Florida
– -$2.91M -99,818 Closed
MIM
56
Monashee Investment Management
Massachusetts
– -$2.18M -74,621 Closed
Alyeska Investment Group
57
Alyeska Investment Group
Illinois
– -$1.46M -50,167 Closed
DKCM
58
Davidson Kempner Capital Management
New York
– -$1.17M -40,000 Closed
MWNA
59
Marshall Wace North America
New York
– -$1.06M -36,355 Closed
LCM
60
Laurion Capital Management
New York
– -$729K -25,000 Closed
SC
61
Sculptor Capital
New York
– -$729K -25,000 Closed
DIM
62
DC Investments Management
Virginia
– -$684K -23,464 Closed
Blackstone Inc
63
Blackstone Inc
New York
– -$598K -20,500 Closed
SM
64
Sabby Management
Florida
– -$473K -16,202 Closed
SG Americas Securities
65
SG Americas Securities
New York
– -$391K -13,400 Closed
KC
66
KCL Capital
New York
– -$292K -10,000 Closed
BCM
67
BlueCrest Capital Management
Jersey
– -$230K -7,891 Closed
Tudor Investment Corp
68
Tudor Investment Corp
Connecticut
– -$219K -7,500 Closed
LTFS
69
Ladenburg Thalmann Financial Services
Florida
– -$88K -3,000 Closed
AAMU
70
Amundi Asset Management US
Massachusetts
– -$29K -1,000 Closed
CCA
71
Catalyst Capital Advisors
New York
– -$7K -240 Closed
Royal Bank of Canada
72
Royal Bank of Canada
Ontario, Canada
– +$613 +22 New
1 2
3

STOK Hedge Fund Activity: Q3 2019 in Review

53 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2019, worth a combined $339M — down 17% from $409M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new STOK positions and 19 closed out — a net gain of 6 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $20.8M. The largest seller was Wellington Management Group, cutting an estimated $7.29M.

  • 53 institutional investors held Stoke Therapeutics (STOK) as of Q3 2019, up from 47 in Q2 2019.
  • Funds reported $339M of Stoke Therapeutics stock for Q3 2019, down 17% quarter-over-quarter.
  • 25 funds opened new Stoke Therapeutics positions in Q3 2019 and 19 closed out, a net change of +6 holders.
  • The largest Stoke Therapeutics buyer in Q3 2019 was Janus Henderson Group, an estimated $20.8M added.
  • The largest Stoke Therapeutics seller in Q3 2019 was Wellington Management Group, an estimated $7.29M sold.

Based on aggregated 13F filings for Q3 2019.